Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
Go back to Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 66.82 -1.27 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $68.09 | 52 Week High | $77.12 | |||
| Open | $67.24 | 52 Week Low | $49.03 | |||
| Day High | $67.72 | P/E | 43.39 | |||
| Day Low | $66.58 | EPS | $1.54 | |||
| Volume | 4,825,368 | |||||
